Despite the potential treatment-related death of two mice, the drug-treated group showed complete tumor suppression and remained tumor-free throughout the trial, which warrants future studies to use this compound for neuroblastoma with wild-type TP53 and MYCN amplification. This evidence concerns the gene MYCN and neuroblastoma.